Dora Bibila, Commercialization Strategy Lead, Corval
Advertisement
Articles by Dora Bibila, Commercialization Strategy Lead, Corval
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly Enters Three Separate Acquisitions Totaling $3.83 Billion
2
The Implications of the Rising GLP-1 Market: Q&A with Kevin Dondarski
3
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
4
What Kinds of Disruption are GLP-1s Expected to Face
5